Business and Finance

Momentum from the previous two years will propel the sector into the rest of 2024, says AM Best analysis.

A Carrum Health/PWC report surveys benefit managers spanning various self-insured employers in an effort to determine ways to improve the cancer treatment experience, especially from a cost perspective.

A cross-sectional study investigates how this supply chain link helps increase Medicare Part D spending on self-administered specialty drugs.

The annual report published by IQVIA examines movement surrounding drug launches and new clinical trials, during the post-pandemic era.

As part of the agreement, Novo will be paid both development and commercial milestone payments for NN-8828, is currently in Phase II of non-dermatological indications.

The financial commitment features construction of new warehouses in Pennsylvania and North Carolina.

The analysis notes that 60% of respondents were setting targets based on AI’s ability to either cut costs or boost productivity.

Roche and Repare came to terms on a deal in June 2022 to develop and commercialize camonsertib, which included a $125 million upfront payment and could have reached up to $1.2 billion based on clinical, regulatory, commercial, and sales milestones.

According to AbbVie, ImmunoGen's entire oncology portfolio could drive long-term revenue growth, giving the company a potential multi-billion dollar drug that is already on the market.

Technavio analysis notes that an increase drug patent expirations could be a contributing factor.

The acquisition expands Merck’s portfolio in the veterinary pharma space.

The deal is expected to help boost supply of Wegovy.

Pharma Commerce travels to Orlando for a pulse-check on this fast-evolving landscape in patient care.

An analysis of the two main new models for pharmacy—unique direct—to-consumer for brands and cash pay for generics—and what members of industry think about them.

A dive into this market reveals that the latest numbers yield promising results—a global value of a worldwide $1.6 trillion—but it will continue to be attributed to past, present, and future healthcare spending.

Leading experts in the sector explore the value of third-party logistics providers when it comes to fortifying pharmaceutical supply chains.

Health Affairs study investigates the consequences of patient medication abandonment surrounding oral HIV pre-exposure prophylaxis.

In order to provide both profitability and medication access, a balancing act is required.

Duplicate rebates have resulted in revenue leakage for manufacturers.

Per the deal, the company establishes Regeneron Cell Medicines, while also providing it with access to the collection’s full development and commercialization rights.

Biogen and partner Eisai will shift focus to advancing Leqembi, the first anti-amyloid beta treatment for Alzheimer disease to be granted traditional approval by the FDA.

New England Journal of Medicine study provides a breakdown of how hospitals—especially those that qualify for discounts under the federal 340B Drug Pricing Program—are able to make a profit off insurer pharmaceutical expenditures.

The latest financial commitment adds 24,000 liters of biologics drug substance-capacity to the company’s network.

The definitive merger agreement was reached in October 2023, with Bristol Myers Squibb acquiring Mirati for $58 per share in cash, for a total equity value of $4.8 billion.

Acquisition is expected to strengthen company’s CDMO business, while establishing a footprint in the generics space.

Acquisition is expected to offer life sciences clients a boost in expertise and insight.

While often portrayed in a negative light, it is important to find a balanced perspective on its role in the pharma sector.

How pharma companies can be successful in financial forecasting, including why these forecasts should be powered by a patient-based approach.

In the face of chronic disease, DTx have the opportunity to provide a lifeline to patients.

MoU aims to align the pharmaceutical and cold chain sectors by boosting operations.